McqMate
These multiple-choice questions (MCQs) are designed to enhance your knowledge and understanding in the following areas: Bachelor of Pharmacy (B. Pharma) .
Chapters
| 1. |
According to Biopharmaceutics Classification System (BCS), Class II drugs have |
| A. | High solubility/High permeability |
| B. | Low solubility /High permeability |
| C. | High solubility /Low permeability |
| D. | Low solubility /Low permeability |
| Answer» B. Low solubility /High permeability | |
| 2. |
………………is the ratio of the mean residence time to the absorption time |
| A. | Absorption number |
| B. | Dissolution number |
| C. | Dose number |
| D. | Intrinsic dissolution |
| Answer» A. Absorption number | |
| 3. |
USP Apparatus 5 is |
| A. | Flow-through- cell |
| B. | paddle over disk |
| C. | Cylinder |
| D. | Paddle |
| Answer» B. paddle over disk | |
| 4. |
In vitro dissolution rate studies on drug product are useful in bioavailability evaluation if they are correlated with |
| A. | Disintegration rate |
| B. | In vivo studies in at least 3 species of animals |
| C. | Chemical stability of drugs |
| D. | In vivo studies in human |
| Answer» D. In vivo studies in human | |
| 5. |
The gold coating on a USP Dissolution apparatus - I basket should be: |
| A. | Not more than 2.5 m in thickness |
| B. | Not more than 0.1 mm in thickness |
| C. | Not more than 0.025 m in thickness |
| D. | Not more than 0.22 mm in thickness |
| Answer» A. Not more than 2.5 m in thickness | |
| 6. |
Which of the following is initial step for drug absorption in case of tablet dosage form? |
| A. | Friability |
| B. | Disintegration |
| C. | Dissolution |
| D. | None of these |
| Answer» B. Disintegration | |
| 7. |
Under the concept biopharmaceutics, hydrophobic drugs are |
| A. | Permeation rate limited |
| B. | Dissolution rate limited |
| C. | Both |
| D. | Initially permeation then dissolution rate limited |
| Answer» B. Dissolution rate limited | |
| 8. |
When a drug is administered by the intravenous route then an absolute bioavailability will be |
| A. | 1 |
| B. | 0 |
| C. | 2 |
| D. | 3 |
| Answer» A. 1 | |
| 9. |
Which of the following methods are used to determine Area Under curve? |
| A. | Cut and weigh method |
| B. | Trapezoidal method |
| C. | Integration method |
| D. | All of the above |
| Answer» D. All of the above | |
| 10. |
Apparatus 5 of dissolution apparatus is known as |
| A. | Paddle over disk |
| B. | Flow-through- cell |
| C. | Reciprocating disk |
| D. | Basket |
| Answer» A. Paddle over disk | |
| 11. |
Bioavailability differences among oral formulations of a drug are most likely to occur if the drug |
| A. | Is freely water soluble |
| B. | Is completely absorbed |
| C. | Is incompletely absorbed |
| D. | Undergoes little first-pass metabolism |
| Answer» C. Is incompletely absorbed | |
| 12. |
Bioavailability is expressed by formula |
| A. | AUC IV / AUC oral |
| B. | AUC ora1 X AUC IV |
| C. | AUC ora1 / AUC IV |
| D. | None of the above |
| Answer» A. AUC IV / AUC oral | |
| 13. |
The comparison of bioavailability between two dosage forms. |
| A. | Bioequivalence |
| B. | Bioavailability |
| C. | Biopharmaceutics |
| D. | Biological |
| Answer» A. Bioequivalence | |
| 14. |
The relative amount of an administered dose that reaches the general circulation and the rate at which this occurs. |
| A. | Biological |
| B. | Bioavailability |
| C. | Biopharmaceutics |
| D. | Bioequivalency |
| Answer» B. Bioavailability | |
| 15. |
Bioavailability of an intravenous drug is always 100% by definition because: |
| A. | Bioavailability measures the amount of substance that reaches the bloodstream. |
| B. | Absolute bioavailability is 50%, for any drug taken intravenously |
| C. | Absolute bioavailability is a much more important measure than relative bioavailability |
| D. | Intravenous administration gets the drug into your bloodstream the fastest. |
| Answer» D. Intravenous administration gets the drug into your bloodstream the fastest. | |
| 16. |
Comparison of the rate and extent of the absorption of drug from the formulation under study to the data of a reference standard that is given intravenously is known as: |
| A. | Biopharmaceutics |
| B. | Relative bioavailability |
| C. | Absolute bioavailability |
| D. | Bioavailability |
| Answer» C. Absolute bioavailability | |
| 17. |
If the Relative Bioavailability is 1, it indicates: |
| A. | Bioavailability of dosage form of one drug is same as that of the other dosage form |
| B. | Complete binding of the drugs to the proteins as compared to the standard drug |
| C. | Complete bioavailability of the drug |
| D. | Complete distribution of the drug |
| Answer» A. Bioavailability of dosage form of one drug is same as that of the other dosage form | |
| 18. |
What would be the order of greater or lesser bioavailability of the dosage forms? |
| A. | Intravenous > rectal > oral > topical |
| B. | Intravenous > oral > rectal > topical |
| C. | Intravenous > topical > rectal > oral |
| D. | Oral > intravenous > rectal > topical |
| Answer» B. Intravenous > oral > rectal > topical | |
| 19. |
…………decreases bioavailability of tetracycline. |
| A. | Lactose |
| B. | DCP |
| C. | Starch |
| D. | MCC |
| Answer» B. DCP | |
| 20. |
The term bioavailability refers to the…………. |
| A. | relationship between the physical and chemical properties of a drug and the systemic absorption of the drug |
| B. | measurement of the rate and amount of therapeutically active drug that reaches the systemic circulation |
| C. | movement of drug into the body tissues over time |
| D. | dissolution of a drug in the gastrointestinal tract |
| Answer» B. measurement of the rate and amount of therapeutically active drug that reaches the systemic circulation | |
| 21. |
The reasons determining bioavailability are….. |
| A. | Rheological parameters of blood |
| B. | Amount of a substance obtained orally and quantity of intakes |
| C. | Extent of absorption and hepatic first-pass effect |
| D. | Glomerular filtration rate |
| Answer» C. Extent of absorption and hepatic first-pass effect | |
| 22. |
Bioavailability is defined as….. |
| A. | Rate of drug absorption |
| B. | Rate of drug distribution |
| C. | Rate of drug elimination |
| D. | Rate and extent of absorption |
| Answer» D. Rate and extent of absorption | |
| 23. |
The rate of drug bioavailability is most rapid when the drug is formulated as a….. |
| A. | controlled released product |
| B. | hard gelatin capsule |
| C. | tablet |
| D. | solution |
| Answer» D. solution | |
| 24. |
The drug concentration between MEC and MSC represents the…. |
| A. | Therapeutic Index |
| B. | Therapeutic range |
| C. | Therapeutic outcome |
| D. | Therapeutic ratio |
| Answer» B. Therapeutic range | |
| 25. |
Dissolution test apparatus I as per IP is….. |
| A. | Paddle |
| B. | Basket |
| C. | Rotating basket |
| D. | Rotating paddle |
| Answer» A. Paddle | |
| 26. |
Non-invasive measurement of drug concentration includes ……….sampling. |
| A. | hair |
| B. | urine |
| C. | saliva |
| D. | All of the above |
| Answer» D. All of the above | |
| 27. |
Ex-vivo models refer to……. |
| A. | in the body |
| B. | in the computer |
| C. | outside the body |
| D. | none of the above |
| Answer» C. outside the body | |
| 28. |
USP dissolution test apparatus type-II is also called as….. |
| A. | Hansen paddle type |
| B. | paddle over disc |
| C. | Rotating basket type |
| D. | none of the above |
| Answer» A. Hansen paddle type | |
| 29. |
Bioavailability from IV route is……% |
| A. | 10 |
| B. | 100 |
| C. | 1000 |
| D. | 10000 |
| Answer» B. 100 | |
| 30. |
Bioavailability of drug from topical administration is affected by….. |
| A. | Skin condition |
| B. | Topical vehicle |
| C. | Application condition |
| D. | all of the above |
| Answer» D. all of the above | |
| 31. |
What is bioavailability? |
| A. | The time of absorption of the drug from its dosage form |
| B. | The rate of absorption of the unchanged drug from its dosage form |
| C. | The time of absorption of the unchanged drug from its dosage form |
| D. | The rate of absorption of the drug from its dosage form |
| Answer» B. The rate of absorption of the unchanged drug from its dosage form | |
| 32. |
What is the equation of bioavailable fraction? |
| A. | 1/Bioavailable dose |
| B. | 1/Administered dose |
| C. | Bioavailable dose/Administered dose |
| D. | Administered dose/Bioavailable dose |
| Answer» C. Bioavailable dose/Administered dose | |
| 33. |
Which of the following is not an objective of bioavailability studies? |
| A. | Primary stages of development of suitable dosage form for new drug |
| B. | Determination of the influence of excipients, patient-related factors, etc |
| C. | Development of new formulations of the existing drugs |
| D. | Control the quantity of the drug to be administered |
| Answer» D. Control the quantity of the drug to be administered | |
| 34. |
Single-dose bioavailability studies are simple and common. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» A. True | |
| 35. |
Multiple dose study is better since we can understand the peak, valley, drug blood levels, etc. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» A. True | |
| 36. |
Which of the following is the pharmacodynamics method of studying bioavailability? |
| A. | Acute pharmacologic response |
| B. | Plasma-level time studies |
| C. | Urinary excretion studies |
| D. | Stool excretion studies |
| Answer» A. Acute pharmacologic response | |
| 37. |
Which of the following is not an important parameter of plasma level time studies? |
| A. | Cmax |
| B. | Tax |
| C. | The area under the plasma level-time curve |
| D. | Steady state level |
| Answer» D. Steady state level | |
| 38. |
What is the equation for bioavailability? |
| A. | [AUC]std Dstd τtest / [AUC]test Dtest τstd |
| B. | [AUC]test Dtest τstd / [AUC]std Dstd τtest |
| C. | [AUC]test Dstd τtest / [AUC]std Dtest τstd |
| D. | 1 / [AUC]std Dtest τstd |
| Answer» C. [AUC]test Dstd τtest / [AUC]std Dtest τstd | |
| 39. |
The urinary excretion of the unchanged drug is directly proportional to the plasma concentration of a drug. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» A. True | |
| 40. |
Which of the following will not be a parameter that should be examined for urinary excretion data? |
| A. | (dXu/dt) max |
| B. | (tu)max |
| C. | Xu |
| D. | Cmax |
| Answer» D. Cmax | |
| 41. |
Which of the following is not measured in acute pharmacological response study? |
| A. | ECG |
| B. | EEG |
| C. | Pupil diameter |
| D. | Serum drug level |
| Answer» D. Serum drug level | |
| 42. |
Therapeutic response is based on observing the clinical response to a drug formulation. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» A. True | |
| 43. |
In vitro determination of bioavailability by dissolution rate is not the best way to determine therapeutic efficacy. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» B. False | |
| 44. |
The time period for which the plasma concentration of drug remains above minimum effective concentration is known as ______________ |
| A. | Onset of time |
| B. | Onset of action |
| C. | Duration of drug of action |
| D. | Therapeutic range |
| Answer» C. Duration of drug of action | |
| 45. |
Poor bioavailability means poor aqueous solubility. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» A. True | |
| 46. |
A drug with poor stability means higher bioavailability. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» B. False | |
| 47. |
Which of the following is not an approach for overcoming bioavailability problems? |
| A. | Pharmaceutic approach |
| B. | Pharmacokinetic approach |
| C. | Biologic approach |
| D. | Partition coefficient approach |
| Answer» D. Partition coefficient approach | |
| 48. |
What will be the particle size after micronization of drugs? |
| A. | 1-10 micron |
| B. | 10-20 micron |
| C. | 20-30 micron |
| D. | 1-5 micron |
| Answer» A. 1-10 micron | |
| 49. |
What is the principle behind the use of surfactants? |
| A. | Reducing the size of solid drug particles |
| B. | Enhancing the dissolution rate by promoting wetting |
| C. | Improving solubility |
| D. | Alter the pH of the microenvironment |
| Answer» B. Enhancing the dissolution rate by promoting wetting | |
| 50. |
Salts improve solubility and dissolution characteristics. |
| A. | True |
| B. | False |
| C. | none |
| D. | all |
| Answer» A. True | |
Done Studing? Take A Test.
Great job completing your study session! Now it's time to put your knowledge to the test. Challenge yourself, see how much you've learned, and identify areas for improvement. Don’t worry, this is all part of the journey to mastery. Ready for the next step? Take a quiz to solidify what you've just studied.